Plasmid Or Episome Contains Dna Targeting Homologous Recombination To Bacteriophage, Viral, Or Chromosomal Dna Within A Microorganism Patents (Class 435/477)
  • Patent number: 6100063
    Abstract: A prokaryotic cell expressing a gene of interest and comprising at least two copies of said gene on the chromosome.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: August 8, 2000
    Assignee: Novo Nordisk A/S
    Inventor: Steen Troels J.o slashed.rgensen
  • Patent number: 6090629
    Abstract: A method for producing gene targeting constructs in bacterial by way of homologous recombination between bacterial phage and plasmids.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 18, 2000
    Assignee: Amgen, Inc.
    Inventor: Richard Woychik
  • Patent number: 6083924
    Abstract: The invention provides dnaB polypeptides and polynucleotides encoding dnaB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing dnaB polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: March 12, 1998
    Date of Patent: July 4, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: David Lawrence Earnshaw, Earl William May, Damien McDevitt
  • Patent number: 6083718
    Abstract: Novel methods and novel industrial unicellular microorganism strains, particularly industrial Bacillus strains, are provided for enhanced production of endogenous and exogenous polypeptides. Cloning vehicles containing the gene expressing the polypeptide of interest are introduced into a compatible host. Transformed hosts harboring the introduced vehicle in a stable way by integration of the vehicle into the host cells chromosome are selected. Efficient transfer of the vehicle containing the gene of interest is achieved, with the resulting industrial strain transformants being effective, stable producers of the desired polypeptide product.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: July 4, 2000
    Assignee: Gist-Brocades, N.V.
    Inventors: Johan Pieter Marinus Sanders, Johannes Abel Van Den Berg, Peter Michael Andreoli, Yvonne Johanna Vos, Jan Hendrik Van Ee, Leo J. S. M. Mulleners
  • Patent number: 6069010
    Abstract: The present invention provides a vector system that is useful for the generation of mutations in a recombination-based construction method. The invention further includes the incorporation of mutations generated by the method of the present invention into mouse embryonic stem cells and transgenic mice.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: May 30, 2000
    Assignee: AxyS Pharmaceuticals, Inc.
    Inventor: Theodore Kyu Choi
  • Patent number: 6033883
    Abstract: Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: March 7, 2000
    Assignee: KOSAN Biosciences, Inc.
    Inventors: Philip J. Barr, Daniel V. Santi, Gary W. Ashley, Rainer Ziermann
  • Patent number: 6031149
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: February 29, 2000
    Assignees: Institut National De La Sante Et De La Recherche Medicale, Centre National De La Recherche Scientifique, Universite Louis Pasteur, E.R. Squibb & Sons, Inc.
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • Patent number: 5989889
    Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having tripeptide aminopeptidase activity. The invention also relates; to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: November 23, 1999
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Michael Rey, Elizabeth Golightly
  • Patent number: 5981281
    Abstract: Provided herein is a method to produce knockout mutations at targeted sites in the genome of Streptococcus pneumoniae.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Richard Henry Baltz, Jo Ann Hoskins, Patricia Jean Solenberg, Patti Jean Treadway
  • Patent number: 5965444
    Abstract: A DNA construct wherein a DNA fragment which is recombinable in yeast chromosomal DNA is directly or indirectly linked at both ends of a DNA fragment which comprises a pair of R sensitive sequences oriented in the same direction and flaking both an R gene placed under the control of an inducible promoter and an expressible selective marker gene, which is a DNA construct designed with the R sensitive sequences non-symmetrically shortened, so that no functionable R sensitive sequence remains after the R sensitive sequence recombination has occurred by expression of the R gene and the selective marker has been removed. Since no functionable R sensitive sequence remains after removal of the selective marker, recombination does not occur again, and thus the same selective marker may be used for multiple insertions of foreign genes.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: October 12, 1999
    Assignee: Suntory Limited
    Inventors: Toshihiko Ashikari, Hiroto Kondo, Keiko Sakakibara, Hiroyuki Araki, Yasuji Oshima
  • Patent number: 5958728
    Abstract: The present invention relates to methods of producing a polypeptide, comprising: (a) cultivating a mutant of a Bacillus cell, wherein the mutant (i) comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the biosynthesis or secretion of a surfactin or isoform thereof under conditions conducive for the production of the polypeptide and (ii) the mutant produces less of the surfactin or isoform thereof than the Bacillus cell when cultured under the same conditions; and (b) isolating the polypeptide from the cultivation medium. The present invention also relates to mutants of Bacillus cells and methods for producing the mutants.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: September 28, 1999
    Assignee: Novo NordiskBiotech, Inc.
    Inventors: Alan Sloma, David Sternberg, Lee F. Adams, Stephen Brown
  • Patent number: 5955348
    Abstract: Strains of Pseudomonas have been genetically engineered to have enhanced biocontrol properties. The strains of the invention are particularly effective against plant pathogenic fungi such as species of Rhizoctonia and Pythium, because the strains produce enhanced amounts of antifungal metabolites such as pyrrolnitrin that are active against these fungal pathogens. Both the genetically modified biocontrol strains and the antifungal metabolites can be used as active agents for biocontrol compositions.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 21, 1999
    Assignee: Novartis AG
    Inventors: James Madison Ligon, Nancy R. Torkewitz, Dwight Steven Hill, Thomas Deane Gaffney, Jill Michelle Stafford
  • Patent number: 5948682
    Abstract: The present invention relates to the use of a class of genes called oil body protein genes that have unique features. The discovery of these features allowed the invention of methods for the production of recombinant proteins wherein a protein of interest can be easily separated from other host cell components. The invention is further exemplified by methods for exploitation of the unique characteristics of the oil body proteins and oil body genes for expression of polypeptides of interest in many organisms, particularly plant seeds. Said polypeptides may include but are not limited to: seed storage proteins, enzymes, bioactive peptides, antibodies and the like. The invention can also be modified to recover recombinant polypeptides fused to oil body proteins from non-plant host cells. Additionally the invention provides a method of using recombinant proteins associated with seed oil bodies released during seed germination for expression of polypeptides that afford protection to seedlings from pathogens.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: September 7, 1999
    Assignee: Sembiosys Genetics Inc.
    Inventor: Maurice M. Moloney
  • Patent number: 5945339
    Abstract: The invention concerns genes encoding recombinases that can be used to promote homologous recombination in eukaryotic cells. The application teaches methods by which a recombinase of one species can be used to isolate a homologous recombinase of a different species and methods to identify the isolated homologs. Recombinases from Ustilago maydis, Saccharomyces cerevisiae and humans are specifically included in the invention.The invention encompasses the method of producing an isolated recombinase protein in a prokaryotic cell and recovering the product in an active form. The invention also encompasses a genetically engineered gene which encodes a non-naturally occurring recombinase that causes a greater rate of recombination than does the naturally occurring recombinase. The invention further encompasses the use of recombinase proteins and of recombinase genes to promote homologous recombination, including recombination between a host cell genome and a chimeric oligonucleotide, i.e.
    Type: Grant
    Filed: July 13, 1998
    Date of Patent: August 31, 1999
    Assignees: Cornell Research Foundation, Inc., Thomas Jefferson University
    Inventors: William K. Holloman, Eric B. Kmiec
  • Patent number: 5922576
    Abstract: Recombinant adenoviruses provide a versatile system for gene expression studies and therapeutic applications. This invention describes a strategy which simplifies the generation and production of such viruses. A recombinant adenoviral plasmid is generated with a minimum of enzymatic manipulations, employing homologous recombination in bacteria rather than in eucaryotic cells. Following transfections of such plasmids into a mammalian packaging cell line, viral production can be conveniently followed with the aid of green fluorescent protein, encoded by a gene incorporated into the viral backbone. Homogeneous viruses can be obtained from this procedure without plaque purification. This system expedites the process of generating and testing recombinant adenoviruses.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: July 13, 1999
    Assignee: The John Hopkins University
    Inventors: Tong-Chuan He, Bert Vogelstein, Kenneth W. Kinzler
  • Patent number: 5888800
    Abstract: Increased production of a heterologous cellulase is achieved by transforming Bacillus subtilis and Bacillus licheniformis with genetic constructs containing a Bacillus licheniformis ATCC 53926 protease promoter and signal sequence to express alkalophilic cellulase genes.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: March 30, 1999
    Assignee: Henkel Kommanditgesellschaft auf Aktien
    Inventors: C. Ron Wilson, Maria R. Tang, Terri Christianson, Karl-Heinz Maurer, Albrecht Weiss
  • Patent number: 5882653
    Abstract: Avirulent Vibrio cholerae strains of O1 (CVD111) and non-O1 (CVD112 and CVD112RM) serogroups having the DNA of the cholera toxin core and the RS1 sequences of the cholera toxin locus deleted, and further having a DNA encoding a resistance to mercury, and a DNA encoding the cholera toxin B subunit, or a part thereof sufficient to confer immunogenicity, re-inserted in the chromosome. Methods of making the avirulent V. cholerae O1 and non-O1 strains of the invention, and cholera vaccines using these strains.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: March 16, 1999
    Assignee: The University of Maryland System
    Inventors: James B. Kaper, Myron M. Levine
  • Patent number: 5880273
    Abstract: This invention relates to an isolated and purified DNA encoding an amino acid sequence which comprises SEQ. ID. NO:3.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: March 9, 1999
    Assignee: Suntory Limited
    Inventors: Hideki Adachi, Masafumi Tsujimoto, Hiroyuki Arai, Keizo Inoue